



Karlsson, L. C., Soveri, A., Lewandowsky, S., Karlsson, L., Karlsson, H., Nolvi, S., Karukivi, M., Lindfelt, M., & Antfolk, J. (2021). Fearing the Disease or the Vaccine: The Case of COVID-19. *Personality and Individual Differences*, 172, [110590].  
<https://doi.org/10.1016/j.paid.2020.110590>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY-NC-ND

Link to published version (if available):  
[10.1016/j.paid.2020.110590](https://doi.org/10.1016/j.paid.2020.110590)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at <https://doi.org/10.1016/j.paid.2020.110590>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



Contents lists available at ScienceDirect

# Personality and Individual Differences

journal homepage: [www.elsevier.com/locate/paid](http://www.elsevier.com/locate/paid)



## Fearing the disease or the vaccine: The case of COVID-19

Linda C. Karlsson<sup>a,\*</sup>, Anna Soveri<sup>b</sup>, Stephan Lewandowsky<sup>c,d</sup>, Linnea Karlsson<sup>b,e,f</sup>,  
Hasse Karlsson<sup>b,e,g</sup>, Saara Nolvi<sup>b,h,i</sup>, Max Karukivi<sup>b,g</sup>, Mikael Lindfelt<sup>j</sup>, Jan Antfolk<sup>a</sup>

<sup>a</sup> Department of Psychology, Åbo Akademi University, Finland

<sup>b</sup> FinnBrain Birth Cohort Study, Institute of Clinical Medicine, University of Turku, Finland

<sup>c</sup> School of Psychological Science, University of Bristol, United Kingdom

<sup>d</sup> School of Psychological Science, University of Western Australia, Australia

<sup>e</sup> Centre for Population Health Research, University of Turku and Turku University Hospital, Finland

<sup>f</sup> Department of Child Psychiatry, Turku University Hospital and University of Turku, Finland

<sup>g</sup> Department of Psychiatry, Turku University Hospital and University of Turku, Finland

<sup>h</sup> Turku Institute for Advanced Studies, Department of Psychology and Speech-Language Pathology, University of Turku, Finland

<sup>i</sup> Department of Medical Psychology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany

<sup>j</sup> Department of Theological Ethics, Åbo Akademi University, Finland

### ARTICLE INFO

#### Keywords:

COVID-19

Coronavirus

Vaccination intentions

Vaccine hesitancy

Perceived risk

Perceived vaccine safety

### ABSTRACT

As studies indicate that people perceive COVID-19 as a threatening disease, the demand for a vaccine against the disease could be expected to be high. Vaccine safety concerns might nevertheless outweigh the perceived disease risks when an individual decides whether or not to accept the vaccine. We investigated the role of perceived risk of COVID-19 (i.e., perceived likelihood of infection, perceived disease severity, and disease-related worry) and perceived safety of a prospective vaccine against COVID-19 in predicting intentions to accept a COVID-19 vaccine. Three Finnish samples were surveyed: 825 parents of small children, 205 individuals living in an area with suboptimal vaccination coverage, and 1325 Facebook users nationwide. As points of reference, we compared the perceptions of COVID-19 to those of influenza and measles. COVID-19 was perceived as a threatening disease—more so than influenza and measles. The strongest predictor of COVID-19 vaccination intentions was trusting the safety of the potential vaccine. Those perceiving COVID-19 as a severe disease were also slightly more intent on taking a COVID-19 vaccine. Informing the public about the safety of a forthcoming COVID-19 vaccine should be the focus for health authorities aiming to achieve a high vaccine uptake.

### 1. Introduction

Due to the COVID-19 pandemic, the world faces a novel infectious disease, for which there currently is no treatment or herd immunity. The pandemic poses a serious threat to our health and well-being (WHO, 2020a) and researchers are racing to develop and test vaccines against COVID-19 (Callaway, 2020). When vaccines become available, the success of the vaccination program will depend on the public's acceptance of the vaccines. Recent studies have indicated that whereas the majority report they would accept a future vaccine against COVID-19 (Blanchard-Rohner et al., 2020 [pre-print]; Detoc et al., 2020; Dodd et al., 2020; Faasse & Newby, 2020; Freeman et al., 2020; Malik et al., 2020; Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 2020),

6–25% report they would not (Detoc et al., 2020; Faasse & Newby, 2020; Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 2020; The COCONEL Group, 2020; Ward, Alleaume, Peretti-watel, & the COCONEL Group, 2020). Understanding why people feel hesitant towards a vaccine against COVID-19 is of paramount importance, as this can help health authorities boost vaccine acceptance to limit the spread of the disease. Research shows that vaccine acceptance is a complex decision-making process influenced by a wide range of factors (for reviews, see e.g., Betsch et al., 2018; Brewer et al., 2017; Larson et al., 2014; Thomson et al., 2016). The present study will explore the role of two of these key factors—the perceived risk of the disease the vaccine protects against and the perceived safety of the vaccine—in people's acceptance of a vaccine against COVID-19.

\* Corresponding author at: Department of Psychology, Åbo Akademi University, Tehtaankatu 2, 20500 Turku, Finland.

E-mail addresses: [linda.karlsson@abo.fi](mailto:linda.karlsson@abo.fi) (L.C. Karlsson), [anna.soveri@utu.fi](mailto:anna.soveri@utu.fi) (A. Soveri), [stephan.lewandowsky@bristol.ac.uk](mailto:stephan.lewandowsky@bristol.ac.uk) (S. Lewandowsky), [linnea.karlsson@utu.fi](mailto:linnea.karlsson@utu.fi) (L. Karlsson), [hasse.karlsson@utu.fi](mailto:hasse.karlsson@utu.fi) (H. Karlsson), [saara.nolvi@utu.fi](mailto:saara.nolvi@utu.fi) (S. Nolvi), [max.karukivi@utu.fi](mailto:max.karukivi@utu.fi) (M. Karukivi), [mikael.lindfelt@abo.fi](mailto:mikael.lindfelt@abo.fi) (M. Lindfelt), [jan.antfolk@abo.fi](mailto:jan.antfolk@abo.fi) (J. Antfolk).

<https://doi.org/10.1016/j.paid.2020.110590>

Received 7 October 2020; Received in revised form 3 December 2020; Accepted 6 December 2020

Available online 14 December 2020

0191-8869/© 2020 The Authors.

Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### 1.1. Perceived risk of disease

A key determinant in people's vaccination decisions is the risk they associate with the disease the vaccine protects against (Betsch et al., 2018; Thomson et al., 2016). These risk perceptions are often measured as the perceived likelihood of contracting the disease and the perceived severity of the symptoms (Brewer et al., 2007). Risk perceptions are also generally considered to have an emotional dimension, including fear and worry (Loewenstein et al., 2001; Slovic et al., 2004). Research shows that individuals who perceive the risk of contracting a vaccine-preventable disease as low, consider the symptoms of the disease as mild, and worry little about the disease, report less intent to take the vaccines and more often remain unvaccinated (Betsch et al., 2018; Bish et al., 2011; Brewer et al., 2007; Schmid et al., 2017; Thomson et al., 2016).

The risks related to the novel corona virus SARS-CoV-2, which causes COVID-19, have been given considerable attention. On March 11th 2020, the World Health Organization (WHO) declared the outbreak of COVID-19 a pandemic, calling for nations to take "urgent and aggressive" action (WHO, 2020a). The pandemic is a global health crisis that has been covered extensively by the media, and governments and health authorities have taken extensive measures to control the spread of the disease. Therefore it is not surprising that recent studies show that people experience COVID-19 as a threatening disease (Dryhurst et al., 2020; Faasse & Newby, 2020; Glöckner et al., 2020 [pre-print]; Kwok et al., 2020; Park et al., 2020; Wise et al., 2020).

Looking at different aspects of perceived risk, studies have generally found that individuals who perceive COVID-19 to pose a greater risk engage more readily in preventive efforts, such as handwashing and social distancing (Dryhurst et al., 2020; Faasse & Newby, 2020; Harper et al., 2020; Wise et al., 2020). Investigating the relationship between risk perceptions and willingness to take a prospective vaccine against COVID-19, Malik et al. (2020) found that US respondents who rated the disease higher on a risk perception index (consisting of several risk measures) more often reported that they would accept a vaccine against COVID-19. Glöckner et al. (2020 [pre-print]) found that in a German sample, those who perceived their likelihood of becoming infected with COVID-19 as high and the health consequences of the disease as severe had higher vaccination intentions. By contrast, at an early stage of the pandemic, Faasse and Newby (2020) found in an Australian sample that perceived infection risk and perceived disease severity were not meaningful predictors of COVID-19 vaccination intentions. Instead, the more the respondents worried about a widespread outbreak of COVID-19 in Australia, the higher their intentions were to take a COVID-19 vaccine. Also in a French sample, respondents who were very worried about contracting COVID-19 were more likely to agree to take a hypothetical COVID-19 vaccine (Ward et al., 2020). Taken together, the available research indicates that individuals who perceive the risk of COVID-19 as higher, report more willingness to take a prospective vaccine against the disease. However, there is disagreement among the studies concerning which risk-perception components are the most relevant.

### 1.2. Perceived vaccine safety

Another important factor in a vaccination decision is how safe the individual considers the vaccine to be. Individuals who perceive vaccines as safe are more likely to accept vaccinations (Betsch et al., 2018; MacDonald & the SAGE Working Group on Vaccine Hesitancy, 2015; Thomson et al., 2016). Because vaccines against COVID-19 are still under development, information about the safety of the vaccines is limited. Research, however, suggests that when there is a lack of information and experience about the safety of a new vaccine, people tend to form their opinions based on attitudes to existing vaccines. This has been demonstrated for example in studies showing that attitudes to childhood vaccines predict intentions to use a hypothetical vaccine against the Zika virus (Harapan et al., 2019; Ophir & Jamieson, 2018). Another vaccine

that might affect attitudes towards a COVID-19 vaccine is the Pandemrix vaccine. Pandemrix may be particularly relevant because it was implemented during a pandemic of a new infectious disease, the swine flu, only a decade ago (2009–2010). The Pandemrix vaccine caused big controversy due to its association with an increased risk of narcolepsy (Sarkanen et al., 2018). In Finland, where the present study was conducted, the connection between narcolepsy and the Pandemrix vaccine received a great deal of media attention and this may have exacerbated vaccine hesitancy, especially related to influenza vaccines. This hesitancy might, in turn, affect the public's trust in the safety of a potential vaccine against COVID-19.

Another vaccine that has been subject to controversies and may affect the uptake of a COVID-19 vaccine is the MMR vaccine (against measles, mumps, and rubella). This is because a publication in 1998 falsely suggested a link between the vaccine and autism. Although a large amount of research has since shown that the claim of a link is unsubstantiated, some individuals still have unwarranted fears about the vaccine (Karlsson et al., 2019; Wang et al., 2019).

Paradoxically, vaccine safety concerns might be especially common when the prevalence of the vaccine-preventable disease is low and when vaccination programs have been successful. In those cases, the disease is not considered a high risk, and the perceived risks of vaccination might outweigh the perceived risks of the disease (Dubé et al., 2013; Karafillakis & Larson, 2017; MacDonald & the SAGE Working Group on Vaccine Hesitancy, 2015). On the other hand, if the perceived disease risk is very high, individuals might decide to vaccinate despite vaccine concerns.

### 1.3. The current study

The current study includes three separate studies conducted in different samples of adults, which aimed 1) to obtain information on the perceived risk of COVID-19 and trust in the safety of a prospective vaccine against COVID-19 and, 2) to examine if the intention to take a vaccine against COVID-19 is related to the perceived risk of the disease and the perceived safety of the vaccine. As points of reference, the perceived risk of influenza and measles, as well as the perceived safety of the influenza and measles vaccines were also measured.

To get a broad understanding of the role of perceived disease risk on vaccination intentions, and to cover most of the different aspects measured in previous studies, the following main components of disease-risk perceptions were explored: 1) perceived likelihood of infection, 2) perceived disease severity, and 3) disease-related worry. For perceived severity and worry, risk related to both oneself and others were measured.

**Study 1** focused on COVID-19 only. In parents of small children, the study investigated whether the perceived risk of the disease predicted intentions to take a potential COVID-19 vaccine recommended by authorities. As COVID-19 has caused more severe symptoms and higher mortality among older individuals (Centers for Disease Control and Prevention, 2020), age was included as a proxy for objective risk.

In **Study 2**, beyond replicating Study 1, we also measured the perceived risk of influenza and measles. Additionally, the study examined how willing individuals were to take a test-phase COVID-19 vaccine, and whether this willingness was predicted by disease-risk perceptions. The test-phase vaccine was included to represent a vaccine that is likely perceived as less safe, but where perceived disease risk is held constant (the vaccine also protects against COVID-19). The study was conducted in a sample living in an area with sub-optimal uptake of vaccines offered in the national vaccination program.

**Study 3** replicated Study 2 but extended the focus on perceived vaccine safety by including a measure on whether the respondents trusted that a prospective COVID-19 vaccine recommended by authorities would be safe. We also measured the perceived safety of the influenza and measles vaccines. Intentions to take vaccines against COVID-19 (i.e., a recommended vaccine and a test-phase vaccine) were

**Table 1**

Survey questions related to perceived disease risk.

Measure	Survey question	Study
<b>COVID-19</b>		
Perceived likelihood of infection	I think that my likelihood of contracting COVID-19 during the following 12 months is <sup>a</sup>	All
Perceived severity: Personal	How severe would it be for your health if you contracted COVID-19? <sup>b</sup>	All
Perceived severity: General	How severe of a disease do you consider COVID-19 to be? <sup>b</sup>	1, 3
	COVID-19 is a very serious disease. <sup>c</sup>	2
Perceived severity: Likelihood to die	How likely do you think it is that a person who falls ill with COVID-19 dies as a result of the disease? <sup>a</sup>	3
Worry: Fall ill	How much do you worry about falling ill with COVID-19? <sup>d</sup>	All
Worry: Transmit	How much do you worry about transmitting COVID-19 to someone else? <sup>d</sup>	All
<b>Influenza</b>		
Perceived likelihood of infection	If I do not take the influenza vaccine, I think my likelihood of falling ill with influenza during the next season (2020–2021) is <sup>a</sup>	2, 3
Perceived severity: Personal	How severe would it be for your health if you contracted influenza? <sup>b</sup>	2, 3
Perceived severity: General	Influenza is a very serious disease. <sup>c</sup>	2
	How severe of a disease do you consider influenza to be? <sup>b</sup>	3
Perceived severity: Likelihood to die	How likely do you think it is that a person who falls ill with influenza dies as a result of the disease? <sup>a</sup>	3
Worry: Fall ill	How much do you usually worry about falling ill with influenza? <sup>d</sup>	2, 3
Worry: Transmit	How much do you usually worry about transmitting influenza to someone else? <sup>d</sup>	2, 3
<b>Measles</b>		
Perceived likelihood of infection	If my child was unvaccinated against measles, I think the likelihood that my child falls ill with measles during the following 12 months is <sup>a</sup>	2, 3
Perceived severity: Personal	How severe would it be for your child(ren)'s health to contract measles? <sup>b</sup>	2, 3
Perceived severity: General	Measles is a very serious disease. <sup>c</sup>	2
	How severe of a disease do you consider measles to be? <sup>b</sup>	3
Perceived severity: Likelihood to die	How likely do you think it is that a person who falls ill with measles dies as a result of the disease? <sup>a</sup>	3
Worry: Fall ill	How much do you usually worry about your child(ren) falling ill with measles? <sup>d</sup>	2, 3
Worry: Transmit	How much do you usually worry about your child(ren) transmitting measles to someone else? <sup>d</sup>	2, 3

<sup>a</sup> Response alternatives: 1–7 (virtually non-existent; virtually 100%).<sup>b</sup> Response alternatives: 1–5 (not severe at all; very severe).<sup>c</sup> Response alternatives: 1–6 (completely disagree; completely agree).<sup>d</sup> Response alternatives: 1–5 (not at all; very much).

predicted by both perceived disease risk and perceived vaccine safety. Study 3 also included an additional measure of objective disease risk, that is, the prevalence of COVID-19, and investigated whether vaccination intentions were higher among respondents living in a region where COVID-19 was more prevalent than among respondents living in other regions. The study was conducted in a nationwide sample of Facebook users.

All studies were carried out during or directly after the first peak of the coronavirus pandemic in Finland. The data collection of Study 1 took place between May 4th and June 7th, 2020, Study 2 between March 30th and April 12th, 2020, and Study 3 between April 3rd and 17th, 2020. During Studies 2 and 3, the highest numbers of new COVID-19 cases of the first pandemic wave (~900 per week) were observed, and the total number of cases more than doubled (Finnish Institute for Health and Welfare, 2020). Measures put in place by the Finnish government at the time included closing of schools, limiting public gatherings to a maximum number of 10 individuals, and prohibiting unnecessary travel to and from Uusimaa—the region with the most rapid increase in COVID-19 prevalence (Finnish Government, 2020a, 2020b). During Study 1, the weekly incidence of COVID-19 decreased from 600 to 145.

Because of the acute nature of the pandemic at the time of data collection, it was hypothesized that individuals would perceive COVID-19 to carry a greater risk compared to influenza and measles. Initial mortality estimates for COVID-19 provided by the WHO were also higher, at around 3.4%, compared to influenza and measles (mortality rates well under 1%; (Centers for Disease Control and Prevention, 2019; WHO, 2020b)). It was also hypothesized that individuals who perceive the risk of COVID-19 as high (as measured by the three aspects of perceived risk) and trust that a prospective COVID-19 vaccine would be safe have higher intentions to vaccinate against COVID-19. Lastly, because the actual risk increases with age and prevalence of COVID-19, higher age and living in an area with higher COVID-19 prevalence were expected to be associated with higher vaccination intentions.

## 2. General method

All data were collected through surveys. The surveys mainly consisted of questions probing topics related to the coronavirus pandemic. The relevant measures, which were developed by the authors, are presented in the following sections.

## 3. Study 1 method

### 3.1. Respondents and procedure

In May 2020, 5103 parents from the FinnBrain Birth Cohort Study (Karlsson et al., 2018) were invited to an electronic survey including questions related to the coronavirus pandemic. The parents were asked to participate as they had previously (in 2018) been invited to a survey concerning attitudes to vaccines. The survey was open for five weeks. A total of 856 (16.8%) parents responded, but 31 (3.6%) did not answer the questions relevant for the present study and were excluded. The final sample size was, thus, 825. The mean age of the sample was 37.9 ( $SD = 4.75$ , range = 23–55; see Table S1 in the online supplemental material for demographics). Ethical approval for the study was obtained from the Ethics Committee of the Hospital District of Southwest Finland. Respondents gave their informed consent to participate in the electronic survey. They did not receive any compensation for their participation.

### 3.2. Measures

#### 3.2.1. Perceived disease risk

The questions concerning perceived disease risk are presented in Table 1. We formulated the questions on perceived likelihood and severity of disease following the recommendations by Brewer et al. (2007). The respondents were asked to rate their likelihood of contracting COVID-19 within the upcoming 12 months (*perceived likelihood of infection*). As previous research has indicated that a 7-point verbal

scale for perceived likelihood of infection best predicts vaccination behavior (Weinstein et al., 2007), the response alternatives ranged from 1 to 7 (1 = *virtually non-existent*, 2 = *very small*, 3 = *small*, 4 = *medium sized*, 5 = *large*, 6 = *very large*, 7 = *virtually 100%*). To measure *perceived severity*, the respondents were asked how severe they expected COVID-19 to be for their own health (perceived personal severity) and how severe of a disease they perceived COVID-19 to be in general (perceived general severity). The respondents answered on a scale from 1 to 5 (1 = *not severe at all*, 2 = *somewhat severe*, 3 = *quite severe*, 4 = *severe*, 5 = *very severe*). Lastly, how much respondents *worried* about falling ill with or transmitting COVID-19 to someone else was measured on a scale from 1 to 5 (1 = *not at all*, 2 = *somewhat*, 3 = *quite much*, 4 = *much*, 5 = *very much*).

### 3.2.2. Vaccination intention

To measure intentions to accept a vaccine against COVID-19, the respondents were asked “How likely do you consider it to be that you would take a vaccine against COVID-19, if such a vaccine was available, free of charge, and recommended to everyone by the authorities?”. Response alternatives ranged from 1 to 5 (1 = *very unlikely*, 2 = *not that likely*, 3 = *hard to say*, 4 = *quite likely*, 5 = *very likely*).

### 3.3. Statistical analysis

All analyses for Studies 1–3 were carried out in R, version 3.5.1 (R Core Team, 2018). In Study 1, we conducted a linear regression analysis with COVID-19 vaccination intentions as the outcome measure and the perceived disease-risk measures and age as predictors. Gender (1 = female; 2 = male) was included as a predictor because women have been found to perceive COVID-19 as a greater health risk than men (Galasso et al., 2020). On the other hand, the actual risk of COVID-19 has been found greater for men (Griffith et al., 2020).

## 4. Study 1 results

The parents' responses to the question on intentions to take a recommended vaccine against COVID-19 are presented in Table 2. Fig. 1 and Supplementary Table S2 show the distribution of responses to the five measures on the perceived risk of COVID-19. Zero-order correlations between all measures can be found in Table 3.

The results from the regression analysis ( $F[7, 771] = 4.78, p < .001$ , adjusted  $R^2 = 0.03$ ) are shown in Table 4. Of the perceived risk measures, only perceived general severity of the disease was statistically significantly associated with vaccination intentions ( $\beta = 0.12, p = .009$ ).

**Table 2**

Responses to COVID-19 vaccination-intention questions in the three current studies.

Variable	Study 1		Study 2		Study 3	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Test-phase vaccine						
1 Very unlikely	—	—	66	34.02	407	30.95
2	—	—	37	19.07	227	17.26
3	—	—	57	29.38	283	21.52
4	—	—	25	12.89	249	18.94
5 Very likely	—	—	9	4.64	149	11.33
Recommended vaccine						
1 Very unlikely	33	4.32	8	4.12	159	12.05
2	57	7.31	15	7.73	55	4.17
3	114	14.62	20	10.31	143	10.84
4	202	25.90	49	25.26	288	21.83
5 Very likely	374	47.95	102	52.58	674	51.10

*Note.* In Study 1, labels for the options 2 (not that likely), 3 (hard to say), and 4 (quite likely) were provided. Study 1: 45 (5.5%) responses missing. Study 2: 11 (5.4%) responses missing. Study 3: 10 (0.8%) responses missing concerning test-phase vaccine and 6 (0.5%) responses missing concerning recommended vaccine.

Respondents perceiving COVID-19 as more severe in general were more likely to accept the vaccine. Also, men were significantly more likely to intend to vaccinate against COVID-19 than women ( $\beta = 0.12, p < .001$ ).

## 5. Study 1 discussion

Most parents did not expect COVID-19 to pose a great risk for their personal health although they considered the disease as severe and many worried about transmitting it to others. The majority of parents (73.9%) considered the likelihood that they would accept a vaccine against COVID-19 as high (response alternatives 4 and 5 on the 5-point scale), if such a vaccine were available and recommended by authorities. Interestingly, the only aspect of perceived disease risk that played a role in the respondents' vaccination intentions was perceptions of the general severity of COVID-19, so that those who perceived COVID-19 as a more severe disease were more likely to intend to vaccinate. Also, men had higher vaccination intentions than women. Both associations were, however, small. The model explained only 3% of the variance in vaccination intentions. None of the variables concerning the respondents' personal health predicted intentions to vaccinate. It is worth noting that the age distribution of the sample was narrow, and the respondents were relatively young, with 96.4% being between 30 and 49 years old (Supplementary Table S1). Study 1, therefore, suggested that the motivating factor to get vaccinated against COVID-19 is not related to how severe people perceive the disease to be for their own health, but rather to how serious they think the disease is for people in general—at least in this relatively young sample.

Study 2 used a sample with a broader age range. In Study 2, people's perceptions of COVID-19 were compared to those concerning influenza and measles. Vaccine safety was also included by examining how willing individuals were to accept a test-phase COVID-19 vaccine—a vaccine likely considered less safe because of the ongoing tests.

## 6. Study 2 method

### 6.1. Respondents and procedure


In April 2019, 5000 18–65-year-old individuals living in the Pietarsaari region in Finland were invited to an online survey on vaccine attitudes. The region was originally targeted because of the lower uptake of several vaccines included in the national vaccination program compared to other Finnish regions. A total of 1139 (22.8%) invitees responded to the survey and 335 (29.4%) consented to being contacted again and provided a valid e-mail address. On March 30th, 2020, these 335 respondents were invited to an online survey on the coronavirus pandemic. The survey was open for two weeks and 205 (61.2%) individuals replied. No compensation for participation was provided. In Study 2, 110 (29.4%) respondents were between 50 and 65 years old (compared to Study 1, where 99% of the respondents were younger than 50 years; see Supplementary Table S1 for sample descriptives), and 137 (66.8%) reported having children. Ethical approval was received from the Board for Research Ethics at Åbo Akademi University. Informed consent to participate was given electronically.

### 6.2. Measures

#### 6.2.1. Perceived disease risk

*Perceived likelihood of infection* with, *perceived severity* of, and *worry* about COVID-19 were measured with the same questions and response alternatives as in Study 1, with the exception that the measure of perceived general severity was formulated as a statement instead of a question. The respondents indicated whether they agreed with the statement on a 6-point scale with the anchors 1 (*completely disagree*) and 6 (*completely agree*). Additionally, corresponding questions related to influenza and measles were administered (Table 1). The measures of the perceived risk of COVID-19 were not administered if the respondent





**Fig. 1.** Perceived disease risk and perceived vaccine safety. Violin plots of the responses to the questions on perceived risk of COVID-19 and the perceived safety of a recommended COVID-19 vaccine including dots for means and bars for standard deviations. For Studies 2 and 3, violin plots for influenza and measles are also presented. The outer borders of the violin shapes represent the frequency of responses.

reported having tested positive for the disease. The questions related to measles were only administered to respondents who reported having children, except for the question on the general severity of measles that was presented to all respondents.

6.2.2. Vaccination intention

The question on intentions to accept a recommended COVID-19 vaccine differed slightly from that in Study 1 and read: “Imagine a hypothetical scenario where the authorities recommend a new vaccine against COVID-19 free of charge. How likely do you consider it to be that you would accept such a vaccine?”. Willingness to take a test-phase vaccine against COVID-19 was measured with the question: “Imagine a hypothetical scenario where you would be offered the possibility to participate in a trial of a new vaccine against COVID-19 that is under

development. How likely do you consider it to be that you would accept such a vaccine?”. Respondents answered on a 5-point scale with the anchors 1 (*very unlikely*) and 5 (*very likely*).

6.3. Statistical analyses

We tested the difference between the respondents’ willingness to take a recommended COVID-19 vaccine and a test-phase vaccine using paired *t*-tests. Then, whether the perceived disease-risk measures, age, and gender (1 = female; 2 = male) predicted intentions to take a recommended COVID-19 vaccine and a test-phase vaccine was investigated in two linear regression analyses. In Study 2, the age measure was categorical, as the respondents reported which of the following age spans they belonged to: 18–29, 30–39, 40–49, or 50–59 years old, or 60+ years

**Table 3**  
Zero-order correlations between all measures in Study 1.

Variable	1	2	3	4	5	6	7
1. Perceived likelihood of infection	–						
2. Perceived severity: Personal	<b>0.19</b>	–					
3. Perceived severity: General	<b>0.18</b>	<b>0.52</b>	–				
4. Worry: Fall ill	<b>0.29</b>	<b>0.62</b>	<b>0.49</b>	–			
5. Worry: Transmit	<b>0.28</b>	<b>0.30</b>	<b>0.40</b>	<b>0.52</b>	–		
6. Vaccination intentions: Recommended vaccine	<b>0.08</b>	<b>0.09</b>	<b>0.12</b>	0.05	0.04	–	
7. Age	–0.02	<b>0.13</b>	0.02	0.01	–0.09	<b>0.10</b>	–

Note. Pearson's  $r$  correlations. Bolded correlations are statistically significant at  $p < .05$ .

old. The variable was dummy coded so that each age span was compared to the preceding age span.

Additional analyses can be found in the online supplementary material. In these analyses, we statistically tested the differences in risk perceptions between the diseases (Tables S4 and S5). Furthermore, we investigated whether intentions to take the influenza vaccine for oneself, and intentions to accept childhood vaccines for one's children (Table S3) were predicted by their respective perceived risk measures, respondent age, and gender (Table S6).

## 7. Study 2 results

Table 2 shows the responses to the questions on COVID-19 vaccination intentions. The distributions of responses to the questions on perceived disease risk are shown in Fig. 1 and in Supplementary Table S2. Zero-order correlations between all measures related to COVID-19 are shown in Table 5.

Respondents reported a significantly higher intention to take a recommended vaccine against COVID-19 than a test-phase vaccine ( $t[193] = 21.40, p < .001$ ). The difference between the two types of vaccines was large ( $d = 1.53$ ).

The results from the two linear regression analyses with intentions to take a test-phase vaccine ( $F[10, 177] = 4.17, p < .001$ , adjusted  $R^2 = 0.14$ ) and a recommended vaccine ( $F[10, 177] = 5.31, p < .001$ , adjusted  $R^2 = 0.19$ ) against COVID-19 as outcomes are presented in Table 4. Respondents who perceived COVID-19 as a more severe disease ( $\beta = 0.23, p = .004$ ), who worried more about transmitting COVID-19 ( $\beta = 0.19, p = .032$ ), and who were male ( $\beta = 0.26, p < .001$ ) were more likely to accept a test-phase COVID-19 vaccine. The same variables also significantly predicted willingness to accept a COVID-19 vaccine recommended by authorities, as those perceiving COVID-19 as more severe ( $\beta = 0.24, p = .002$ ), who worried more about transmitting the disease ( $\beta = 0.26, p = .003$ ), and male respondents ( $\beta = 0.23, p = .001$ ) had higher intentions to accept a recommended vaccine. In addition, individuals in their 40s reported significantly higher intentions to accept the vaccine than those in their 30s ( $\beta = 0.24, p = .012$ ).

## 8. Study 2 discussion

Respondents did not consider COVID-19 to constitute a high risk to their personal health, but the great majority (77.8%) considered the likelihood that they would take a recommended COVID-19 vaccine as high. Only ~18% reported a high likelihood for accepting a test-phase vaccine if offered. Considering the high acceptance of a recommended vaccine among the respondents, as well as their willingness to be contacted for research purposes and the high response rate, this sample might not be representative of the general population in the Pietarsaari region.

As in Study 1, the perceived risk of COVID-19 to the respondent's own health did not predict vaccination intentions. Instead, those who believed that COVID-19 was a severe disease, worried about transmitting it to others, and were male, were more likely to accept a test-phase and a recommended vaccine against COVID-19. The variables accounted for 14% of the variance in willingness to take a test-phase vaccine, and 19% of the variance in willingness to take a vaccine recommended by authorities.

In summary, the results from Study 2 are in line with the conclusions from Study 1, suggesting that a more important factor in predicting whether people will accept a COVID-19 vaccine is how threatening they consider the disease to be to others than how threatening they consider it to be for themselves. This finding was even clearer in Study 2, where both variables that measured perceived risk of COVID-19 to others, played a role in the intentions to vaccinate. However, also these respondents were relatively young with the majority being below 50 years of age. The low willingness to accept a test-phase vaccine indicates that when vaccine safety is less certain, vaccination rates might drop dramatically even though the disease is considered severe.

Study 3 further examined the role of perceived vaccine safety by including a question probing how much the respondents trust that a recommended vaccine against COVID-19 would be safe. Study 3 also included an additional measure of perceived severity (the perceived likelihood of death from the disease) and an objective measure of disease risk (residing in Uusimaa vs. other Finnish region).

## 9. Study 3 method

### 9.1. Respondents and procedure

Respondents were recruited via a marketed Facebook post with a link to an online survey. The post was marketed for two weeks, between the 3rd and 17th of April 2020, and reached 97,408 Facebook users. The survey was viewed by 3305 (3.4%) individuals, of whom 2233 (67.6%) started to fill out the questionnaire. The 1325 individuals who reached the end of the questionnaire (i.e., had responded to questions on the last page of the survey) and answered correctly to an attention check question were included. Their mean age was 47.71 ( $SD = 13.11$ , range = 18–100; see, Supplementary Table S1 for sample descriptives). The Board for Research Ethics at Åbo Akademi University approved the study. Respondents gave their informed consent to participate in the study electronically. They did not receive any compensation for their participation.

### 9.2. Measures

#### 9.2.1. Perceived disease risk

The questions and response alternatives related to *perceived likelihood of infection* with, *perceived severity* of, and *worry* about COVID-19 administered in Study 1 were administered in Study 3 as well (Table 1). The corresponding measures related to influenza and measles were the same as in Study 2, with the exception that the questions on perceived general severity of influenza and measles were reformulated to correspond to the COVID-19 question from Study 1. Furthermore, an additional measure of perceived severity for each disease was included, querying the likelihood of death from COVID-19/influenza/measles. Respondents gave their response on a scale from 1 to 7 (1 = *virtually non-existent*, 2 = *very small*, 3 = *small*, 4 = *medium sized*, 5 = *large*, 6 = *very large*, 7 = *virtually 100%*). The questions on COVID-19 were not administered if the respondent reported having tested positive for the disease. The questions on measles were only administered to respondents with children younger than 18.

#### 9.2.2. Perceived vaccine safety

To measure perceptions of vaccine safety, respondents were presented with the statements "If a vaccine against COVID-19 became part

**Table 4**  
Predictors of COVID-19 vaccination intentions in the three current studies.

Variable	Standardized		Unstandardized		t	p
	$\beta$	95% CI	b	95% CI		
Study 1						
Recommended vaccine <sup>a</sup>						
Likelihood of infection	0.07	[−0.00, 0.15]	0.07	[−0.00, 0.14]	1.95	.052
Perceived severity: Personal	0.04	[−0.05, 0.13]	0.05	[−0.07, 0.18]	0.86	.392
Perceived severity: General	0.12	[0.03, 0.20]	0.14	[0.04, 0.25]	2.62	.009
Worry: Fall ill	−0.05	[−0.15, 0.06]	−0.06	[−0.18, 0.07]	0.88	.379
Worry: Transmit	0.02	[−0.06, 0.11]	0.02	[−0.06, 0.11]	0.51	.607
Age	0.07	[−0.00, 0.14]	0.02	[−0.00, 0.03]	1.90	.057
Gender	0.12	[0.05, 0.20]	0.35	[0.14, 0.55]	3.32	<.001
Study 2						
Test-phase vaccine <sup>b</sup>						
Perceived likelihood of infection	−0.08	[−0.07, 0.24]	0.09	[−0.08, 0.25]	1.05	.296
Perceived severity: Personal	−0.15	[−0.33, 0.03]	−0.19	[−0.41, 0.04]	1.66	.099
Perceived severity: General	0.23	[0.08, 0.38]	0.26	[0.09, 0.44]	2.94	.004
Worry: Fall ill	0.02	[−0.16, 0.21]	0.03	[−0.19, 0.25]	0.23	.817
Worry: Transmit	0.19	[0.02, 0.36]	0.19	[0.02, 0.36]	2.16	.032
Age: 30–39 vs. 18–29	−0.15	[−0.31, 0.00]	−0.50	[−0.99, 0.00]	1.97	.050
Age: 40–49 vs. 30–39	0.02	[−0.16, 0.21]	0.06	[−0.39, 0.51]	0.25	.800
Age: 50–59 vs. 40–49	0.18	[−0.03, 0.39]	0.46	[−0.09, 1.02]	1.65	.101
Age: 60+ vs. 50–59	0.02	[−0.16, 0.20]	0.06	[−0.54, 0.66]	0.20	.839
Gender	0.26	[0.12, 0.41]	0.69	[0.31, 1.06]	3.64	<.001
Recommended vaccine <sup>b</sup>						
Perceived likelihood of infection	0.09	[−0.06, 0.24]	0.09	[−0.06, 0.25]	1.19	.237
Perceived severity: Personal	−0.05	[−0.23, 0.12]	−0.06	[−0.27, 0.14]	0.59	.554
Perceived severity: General	0.24	[0.09, 0.39]	0.26	[0.10, 0.42]	3.19	.002
Worry: Fall ill	0.03	[−0.15, 0.21]	0.04	[−0.17, 0.24]	0.37	.711
Worry: Transmit	0.26	[0.09, 0.42]	0.25	[0.09, 0.41]	3.06	.003
Age: 30–39 vs. 18–29	−0.06	[−0.21, 0.09]	−0.19	[−0.65, 0.27]	0.83	.408
Age: 40–49 vs. 30–39	0.24	[0.05, 0.42]	0.54	[0.12, 0.96]	2.55	.012
Age: 50–59 vs. 40–49	−0.13	[−0.34, 0.07]	−0.33	[−0.85, 0.18]	1.27	.206
Age: 60+ vs. 50–59	0.04	[−0.13, 0.22]	0.14	[−0.41, 0.70]	0.50	.616
Gender	0.23	[0.09, 0.37]	0.57	[0.23, 0.92]	3.28	.001
Study 3						
Test-phase vaccine <sup>c</sup>						
Perceived likelihood of infection	0.07	[0.01, 0.13]	0.08	[0.01, 0.14]	2.29	.022
Perceived severity: Personal	0.03	[−0.06, 0.11]	0.03	[−0.07, 0.14]	0.62	.534
Perceived severity: General	−0.04	[−0.12, 0.05]	−0.06	[−0.18, 0.06]	0.91	.361
Perceived severity: Likelihood to die	0.09	[0.02, 0.16]	0.10	[0.02, 0.19]	2.42	.016
Worry: Fall ill	−0.03	[−0.12, 0.05]	−0.04	[−0.13, 0.06]	0.77	.442
Worry: Transmit	0.00	[−0.08, 0.07]	0.00	[−0.09, 0.09]	0.02	.985
Perceived vaccine safety	0.51	[0.46, 0.57]	0.56	[0.50, 0.63]	17.22	<.001
Prevalence	0.04	[−0.01, 0.09]	0.12	[−0.04, 0.27]	1.51	.132
Age	0.14	[0.09, 0.20]	0.02	[0.01, 0.02]	4.89	<.001
Gender	0.08	[0.02, 0.13]	0.27	[0.08, 0.47]	2.80	.005
Recommended vaccine <sup>d</sup>						
Perceived likelihood of infection	0.05	[0.01, 0.90]	0.06	[0.01, 0.10]	2.42	.016
Perceived severity: Personal	0.06	[−0.01, 0.12]	0.07	[−0.01, 0.14]	1.79	.073
Perceived severity: General	0.07	[0.01, 0.13]	0.10	[0.02, 0.19]	2.42	.016
Perceived severity: Likelihood to die	0.00	[−0.05, 0.05]	0.00	[−0.06, 0.06]	0.01	.990
Worry: Fall ill	0.03	[−0.03, 0.09]	0.03	[−0.04, 0.10]	0.90	.371
Worry: Transmit	−0.00	[−0.06, 0.05]	−0.01	[−0.07, 0.06]	0.17	.863
Perceived vaccine safety	0.72	[0.68, 0.76]	0.78	[0.73, 0.82]	33.67	<.001
Prevalence	0.00	[−0.03, 0.04]	0.01	[−0.10, 0.12]	0.15	.878
Age	0.04	[0.00, 0.09]	0.00	[0.00, 0.01]	2.13	.034
Gender	0.04	[−0.00, 0.08]	0.13	[−0.01, 0.26]	1.82	.069

Note. List-wise deletion of missing values. Statistically significant results are bolded. Gender coded as 1 = female and 2 = male.

<sup>a</sup> *n* = 779.

<sup>b</sup> *n* = 188.

<sup>c</sup> *n* = 973.

<sup>d</sup> *n* = 977.

of the recommended vaccines in Finland, I would trust that it is safe”, “The influenza vaccines are safe”, and “The measles vaccine is safe”. They indicated whether they agree on a 5-point scale with the anchors 1 (*completely disagree*) and 5 (*completely agree*).

### 9.2.3. Disease prevalence

During the time of the data collection, the Uusimaa region had a higher prevalence of COVID-19 than any other Finnish region. Movement to and from Uusimaa was restricted by the government (Finnish

Government, 2020b). The respondents were asked to indicate their region of residence. A variable coded as 1 if they reported living in Uusimaa, or 0 if they did not live in Uusimaa, was created.

### 9.2.4. Vaccination intention

The questions on intentions to accept a recommended vaccine and a test-phase vaccine against COVID-19 were the same as in Study 2.



**Table 5**

Zero-order correlations between measures related to COVID-19 in Study 2.

Variable	1	2	3	4	5	6	7	8
1. Perceived likelihood of infection	–							
2. Perceived severity: Personal	<b>0.22</b>	–						
3. Perceived severity: General	0.10	<b>0.42</b>	–					
4. Worry: Fall ill	<b>0.30</b>	<b>0.57</b>	<b>0.34</b>	–				
5. Worry: Transmit	<b>0.44</b>	<b>0.30</b>	<b>0.21</b>	<b>0.50</b>	–			
6. Vaccination intentions: Recommended vaccine	<b>0.17</b>	0.13	<b>0.27</b>	<b>0.18</b>	<b>0.29</b>	–		
7. Vaccination intentions: Test-phase vaccine	0.09	0.05	<b>0.18</b>	0.07	<b>0.19</b>	<b>0.50</b>	–	
8. Age	–0.08	<b>0.28</b>	<b>0.25</b>	0.04	–0.04	<b>0.15</b>	<b>0.15</b>	–

Note. Pearson's *r* correlations. Bolded correlations are statistically significant at  $p < .05$ .

### 9.3. Statistical analysis

As in Study 2, we compared the respondents' intentions to take a recommended and a test-phase COVID-19 vaccine using paired *t*-tests. Two linear regression analyses were then conducted—one with the recommended COVID-19 vaccine as the outcome, and another with the test-phase COVID-19 vaccine as the outcome. The outcomes were regressed on the measures of perceived risk, perceived vaccine safety, disease prevalence, age, and gender (1 = female; 2 = male). The additional analyses conducted in Study 2 were conducted in Study 3 as well (see, online supplemental material).

## 10. Study 3 results

Responses to the questions on COVID-19 vaccination intentions are shown in Table 2. The distribution of the responses to the questions on perceived risk and perceived vaccine safety are shown in Fig. 1 and Supplementary Table S2. Zero-order correlations between all measures related to COVID-19 are presented in Table 6.

The difference between the respondents' willingness to take a recommended vaccine and a test-phase vaccine against COVID-19 was statistically significant and large ( $t[1314] = 40.20, p < .001, d = 1.11$ ).

Table 4 shows the results from the two regression analyses on predictors of willingness to take a test-phase ( $F[10, 962] = 55.04, p < .001$ , adjusted  $R^2 = 0.36$ ) and a recommended vaccine against COVID-19 ( $F[10, 966] = 201.60, p < .001$ , adjusted  $R^2 = 0.67$ ). Respondents who perceived the likelihood of contracting COVID-19 as higher ( $\beta = 0.07, p = .022$ ), the likelihood of death from COVID-19 as higher ( $\beta = 0.09, p = .016$ ), those who trusted the safety of a prospective vaccine more ( $\beta = 0.51, p < .001$ ), and men ( $\beta = 0.08, p = .005$ ) reported significantly more willingness to accept a test-phase vaccine. In addition, higher age was related to a higher willingness to take a test-phase vaccine ( $\beta = 0.14, p < .001$ ). Concerning the recommended COVID-19 vaccine, respondents who perceived the likelihood of contracting the disease as higher ( $\beta = 0.05, p = .016$ ), who considered COVID-19 a more severe disease ( $\beta = 0.07, p = .016$ ), who had higher trust in the vaccine being safe ( $\beta = 0.72, p < .001$ ), and who were older ( $\beta = 0.04, p = .034$ ) were significantly more likely to accept vaccination.

**Table 6**

Zero-order correlations between measures related to COVID-19 in Study 3.

Variable	1	2	3	4	5	6	7	8	9	10
1. Perceived likelihood of infection	–									
2. Perceived severity: Personal	<b>0.41</b>	–								
3. Perceived severity: General	<b>0.37</b>	<b>0.68</b>	–							
4. Perceived severity: Likelihood die	<b>0.37</b>	<b>0.63</b>	<b>0.67</b>	–						
5. Worry: Fall ill	<b>0.46</b>	<b>0.77</b>	<b>0.65</b>	<b>0.60</b>	–					
6. Worry: Transmit	<b>0.46</b>	<b>0.51</b>	<b>0.59</b>	<b>0.50</b>	<b>0.63</b>	–				
7. Vaccine safety	<b>0.22</b>	<b>0.34</b>	<b>0.48</b>	<b>0.33</b>	<b>0.36</b>	<b>0.37</b>	–			
8. Vaccination intentions: Recommended vaccine	<b>0.27</b>	<b>0.40</b>	<b>0.50</b>	<b>0.35</b>	<b>0.41</b>	<b>0.39</b>	<b>0.81</b>	–		
9. Vaccination intentions: Test-phase vaccine	<b>0.16</b>	<b>0.25</b>	<b>0.29</b>	<b>0.25</b>	<b>0.23</b>	<b>0.22</b>	<b>0.58</b>	<b>0.61</b>	–	
10. Age	–0.12	<b>0.23</b>	<b>0.23</b>	<b>0.16</b>	<b>0.10</b>	–0.06	<b>0.21</b>	<b>0.21</b>	<b>0.25</b>	–

Note. Pearson's *r* correlations. Bolded correlations are statistically significant at  $p < .05$ .

## 11. Study 3 discussion

The majority of the respondents (72.9%) considered the likelihood that they would accept a vaccine against COVID-19 as high, if such a vaccine was offered and recommended by authorities. When it comes to a test-phase vaccine, ~30% considered the likelihood high that they would agree to the vaccine. Vaccine safety showed the strongest relationship with vaccination intentions, explaining 52% of unique variance in intentions to accept a recommended COVID-19 vaccine. The measures of perceived risk of COVID-19 were weakly related to vaccination intentions. As in Studies 1 and 2, the perceived severity measures that reached statistical significance probed the perceived risk of COVID-19 to people in general, and not specifically to oneself. Those perceiving COVID-19 as a severe disease were slightly more likely to intend to take a recommended vaccine, whereas those perceiving the likelihood of death from COVID-19 as higher were slightly more willing to accept a test-phase vaccine. Contrary to the results of Studies 1 and 2, the respondents' perceived risk to contract COVID-19 also predicted vaccination intentions. However, the perceived risk measures accounted for only 0.2–0.8% of the variance in vaccination intentions. The objective risk of contracting COVID-19 was not associated with people's willingness to vaccinate, as there was no difference in vaccination intentions between those living in Uusimaa and those living in regions with lower COVID-19 prevalence.

Furthermore, the older the respondents were, the more likely they were to intend to take the two types of vaccines. The fact that age predicted vaccination intentions in Study 3, but not in Studies 1 and 2, might stem from the fact that Study 3 included a sample with the broadest age range. Also, the power in Study 3 was higher, allowing us to detect smaller effects. Finally, men were slightly more likely to accept a test-phase vaccine than women, whereas there were no significant gender differences in intention to take a recommended COVID-19 vaccine.

## 12. General discussion

The aims of the present study were 1) to examine people's perceptions of the risk of COVID-19 and the safety of a prospective vaccine against COVID-19, and 2) to investigate if the perceived disease risk and

perceived vaccine safety are related to intentions to take a COVID-19 vaccine. As a point of reference, we also measured perceptions of influenza and measles.

Across the current three studies, individuals commonly considered COVID-19 to be a very severe disease, although they expected to experience less severe symptoms themselves. Individuals also worried more about transmitting the disease to others than about falling ill personally. Previous research has found an optimistic bias in risk ratings of COVID-19, as individuals commonly consider their own risks as smaller compared to others (Park et al., 2020).

Approximately  $\frac{3}{4}$  of the individuals considered the likelihood that they would accept a recommended vaccine against COVID-19 to be high (i.e., chose the response alternatives 4 or 5 on the 5-point scale; 73.9% in the sample of parents, 77.8% in the sample in the Pietarsaari region, and 72.9% in the nationwide sample of Facebook users). Other studies have found acceptance rates of 67% in the US (Malik et al., 2020), 81–86% in Australia (Dodd et al., 2020; Faasse & Newby, 2020), and between 62 and 85% in other European countries (Blanchard-Rohner et al., 2020 [pre-print]; Murphy et al., 2020 [pre-print]; Neumann-Böhme et al., 2020). For the test-phase vaccine, the acceptance rates were 17.5% and 30.3% in the present study.

### 12.1. Predictors of vaccination intentions

Importantly, the strongest predictor of intentions to accept a COVID-19 vaccine recommended by authorities was the degree to which respondents trusted the vaccine to be safe. Perceived vaccine safety explained 52% of the variance in intentions to vaccinate. Across the three studies, how serious the respondents thought COVID-19 was for people in general also predicted higher vaccination intentions, but the predictive value was much smaller (explaining 0.5–5.8% of the variance in intention to accept a recommended COVID-19 vaccine). Taken together, this means that individuals who perceive the disease as severe might still choose not to vaccinate if they consider the vaccine unsafe. However, individuals who perceive the vaccine as safe might be willing

to take the vaccine although they would not consider the disease as severe (Fig. 2 visualizes this relationship). In the present study, 15.4% of respondents reported that they did not trust a vaccine against COVID-19 recommended by authorities to be safe, and another 15.4% were unsure. The fact that the acceptance rates of a test-phase vaccine, which might be considered less safe, were considerably lower than those of the recommended vaccines also suggests that vaccine safety plays a major role in willingness to take a COVID-19 vaccine. A recent study of seven European countries found that the majority of individuals who were unsure about whether they would accept a COVID-19 vaccine or not, and those who would reject the vaccine, expressed fear of side effects as the reason for their hesitancy (Neumann-Böhme et al., 2020). Concerns about vaccine safety can, thus, be expected to constitute the largest future challenge for health authorities when trying to achieve a high uptake of a COVID-19 vaccine.


Contrary to expectations, the perceived risk of COVID-19 to one's personal health was not robustly associated with intentions to vaccinate. This contrasts with previous research that has found higher perceived likelihood of infection (Glöckner et al., 2020 [pre-print]) and more worry about contracting COVID-19 (Ward et al., 2020) to predict higher vaccination intentions. However, Faasse and Newby (2020) also found the risk of COVID-19 to one's personal health to be only weakly related to vaccination intentions. The fact age did not show any considerable (linear) association with vaccine acceptance further supports the notion that personal disease risk plays a minor role in the vaccination decision. Even when someone does not expect to experience severe symptoms of COVID-19 themselves, they might still be motivated to vaccinate to protect others from a potentially severe disease.

The practical implication of the above-mentioned results is that, to ensure sufficient uptake of an approved COVID-19 vaccine, communications that underscore the safety of the vaccine are more important than highlighting the risks of the disease. It is, however, worth noting that perceived vaccine safety was moderately correlated with how severe the respondents perceived COVID-19 to be for people in general. Those who perceived the disease as mild, often also perceived the vaccine as unsafe (Fig. 2). If this is because people evaluate the safety of the vaccine in relation to how severe they perceive the disease to be, then it is possible that communication emphasizing the risks of the disease influence vaccine perceptions. However, it is also possible that the relationship between perceived vaccine safety and perceived severity of COVID-19 could be explained by a third variable, such as general lack of trust in information provided by medical authorities.

As respondent age and prevalence of COVID-19 did not show any notable relationship with intentions to accept a recommended COVID-19 vaccine, the present study also suggests that communication on vaccine safety should be directed towards individuals at all ages and geographical areas. Women were less willing to accept COVID-19 vaccination than men, but the size of the gender difference varied between studies, and most of the differences were small. Specifically targeting women in communication on a COVID-19 vaccine might, therefore, not be essential.

### 12.2. Limitations

The present study had some limitations. First, the cross-sectional design did not allow for robust conclusions concerning causality. Second, the fact that the data collections took place during the first peak of the pandemic can be considered both a strength and a limitation. On the one hand, it provided information on individuals' perceptions of COVID-19 during acute circumstances. However, vaccinations against COVID-19 might be introduced at a stage of the pandemic when individuals have been habituated to the threat. Research conducted during the swine flu pandemic indicated that the perceived risk of the swine flu decreased as the pandemic progressed (Bults et al., 2015). Glöckner et al. (2020 [pre-print]) conducted three cross-sectional studies in Germany during the growth stage of the COVID-19 pandemic and when the



**Fig. 2.** COVID-19 vaccination intentions. Perceived general severity of COVID-19 (y-axis) plotted by perceived safety of a prospective COVID-19 vaccine (x-axis) in Study 3. The degree to which the respondents report being likely to accept a vaccine against COVID-19 recommended by authorities is represented by blue (response alternative 4 or 5 on the scale ranging from 1 [very unlikely] to 5 [very likely]), green (response alternative 3), and red (response alternative 1 or 2) dots. Marginal distributions are represented by rugs. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

growth curve flattened. They found that perceived risk of COVID-19 decreased after the pandemic peak. Acceptance rates and associations need to be repeatedly studied as the pandemic develops.

Third, the measures administered were developed by the authors and had not been independently validated. However, the formulation of the questions related to the perceived likelihood and severity of disease followed recommendations on the development of reliable risk-perception measures (Brewer et al., 2007). The remaining measures corresponded to those commonly used in research on the subject. We therefore place confidence in our measures.

Fourth, we did not measure the exact age of respondents in Study 2. The respondents were instead asked to indicate which ten-year age span they belonged to. To account for this, age was dummy coded for the analyses.

Lastly, there were minor discrepancies between the studies in some of the measures. There were two reasons for these discrepancies: 1) the samples in Studies 1 and 2 were part of longitudinal studies and we formulated the questions to enable comparison between the two time points, and 2) in Study 1, the vaccination intention measure was adapted to correspond to the structure of a larger COVID-19 survey.

### 12.3. Conclusions

Across three Finnish samples, individuals perceived COVID-19 as a severe disease and worried about transmitting it to others. Respondents were, however, less concerned about the risk of the disease to their own health, especially in the younger samples. Approximately  $\frac{3}{4}$  of respondents reported they would take a vaccine against COVID-19, if such a vaccine was available and recommended by authorities. The strongest predictor of having high intentions to take a COVID-19 vaccine was trusting the vaccine to be safe. Higher vaccination intentions were also somewhat more likely for respondents perceiving the disease as more severe, than for those considering COVID-19 as a mild disease.

Informing the public about the safety of a forthcoming vaccine is of paramount importance to health authorities planning to roll out large-scale vaccinations in the near future. Highlighting the fact that COVID-19 can have detrimental health consequences for those infected, may also positively affect vaccine uptake although the magnitude of that effect may be smaller.

### Funding

LCK was funded by the doctoral network of Minority Research ([www.abo.fi/en/minority-research/](http://www.abo.fi/en/minority-research/)) at Åbo Akademi University. AS was funded by the Academy of Finland (grant number: 316004; [www.aka.fi/en/](http://www.aka.fi/en/)). ML was funded by the Academy of Finland (grant number: 316726; [www.aka.fi/en/](http://www.aka.fi/en/)) and the Polin Institute ([www.polininstitutet.fi/en/polin-institute/](http://www.polininstitutet.fi/en/polin-institute/)).

### CRedit authorship contribution statement

**Linda C. Karlsson:** Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing - original draft, Writing - review & editing, Visualization. **Anna Soveri:** Conceptualization, Methodology, Investigation, Writing - review & editing, Supervision, Project administration, Funding acquisition. **Stephan Lewandowsky:** Conceptualization, Methodology, Supervision, Writing - review & editing. **Linnea Karlsson:** Funding acquisition, Methodology, Resources, Writing - review & editing. **Hasse Karlsson:** Funding acquisition, Methodology, Resources, Writing - review & editing. **Saara Nolvi:** Investigation, Methodology, Writing - review & editing. **Max Karukivi:** Investigation, Methodology, Writing - review & editing. **Mikael Lindfelt:** Writing - review & editing, Funding acquisition, Project administration. **Jan Antfolk:** Conceptualization, Methodology, Formal analysis, Writing - review & editing, Supervision.

### Declaration of competing interest

None.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.paid.2020.110590>.

### References

- Betsch, C., Schmid, P., Heinemeier, D., Korn, L., Holtmann, C., & Böhm, R. (2018). Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PLoS ONE*, 13(12), 1–32. <https://doi.org/10.1371/journal.pone.0208601>.
- Bish, A., Yardley, L., Nicoll, A., & Michie, S. (2011). Factors associated with uptake of vaccination against pandemic influenza: A systematic review. *Vaccine*, 29(38), 6472–6484. <https://doi.org/10.1016/j.vaccine.2011.06.107>.
- Blanchard-Rohner, G., Caprettini, B., Rohner, D., & Voth, H. (2020). Impact of COVID-19 and health system performance on vaccination hesitancy: Evidence from a two-leg representative survey in the UK. *SSRN Electronic Journal*, 1–40. <https://doi.org/10.2139/ssrn.3627335>.
- Brewer, N. T., Chapman, G. B., Gibbons, F. X., Gerrard, M., McCaul, K. D., & Weinstein, N. D. (2007). Meta-analysis of the relationship between risk perception and health behavior: The example of vaccination. *Health Psychology*, 26(2), 136–145. <https://doi.org/10.1037/0278-6133.26.2.136>.
- Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2017). Increasing vaccination: Putting psychological science into action. *Psychological Science in the Public Interest*, 18(3), 149–207. <https://doi.org/10.1177/1529100618760521>.
- Bults, M., Beaujean, D. J. M. A., Richardus, J. H., & Voeten, H. A. C. M. (2015). Perceptions and behavioral responses of the general public during the 2009 influenza A (H1N1) pandemic: A systematic review. *Disaster Medicine and Public Health Preparedness*, 9(2), 207–219. <https://doi.org/10.1017/dmp.2014.160>.
- Callaway, E. (2020). The race for coronavirus vaccines: A graphical guide. *Nature*, 580, 576–577. <https://doi.org/10.1038/d41586-020-01221-y>.
- Centers for Disease Control and Prevention. (2019). Complications of measles. Retrieved from [https://www.cdc.gov/measles/symptoms/complications.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fabout%2Fcomplications.html](https://www.cdc.gov/measles/symptoms/complications.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fabout%2Fcomplications.html).
- Centers for Disease Control and Prevention. (2020). Coronavirus Disease 2019 (COVID-19): Older adults. Retrieved from <https://www.cdc.gov/coronavirus/2019-ncov/n-eed-extra-precautions/older-adults.html>.
- Detoc, M., Bruel, S., Frappe, P., Tardy, B., Botelho-Nevers, E., & Gagneux-Brunon, A. (2020). Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. *Vaccine*, 38, 7002–7006. <https://doi.org/10.1016/j.vaccine.2020.09.041>.
- Dodd, R., Cvejic, E., Bonner, C., Pickles, K., & McCaffery, K. (2020). Willingness to vaccinate against COVID-19 in Australia. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30559-4](https://doi.org/10.1016/S1473-3099(20)30559-4).
- Dryhurst, S., Schneider, C. R., Kerr, J., Freeman, A. L. J., Recchia, G., van der Bles, A. M., ... van der Linden, S. (2020). Risk perceptions of COVID-19 around the world. *Journal of Risk Research*, 1–13. <https://doi.org/10.1080/13669877.2020.1758193>.
- Dubé, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., & Bettinger, J. A. (2013). Vaccine hesitancy: An overview. *Human Vaccines & Immunotherapeutics*, 9(8), 1763–1773. <https://doi.org/10.4161/hv.24657>.
- Faasse, K., & Newby, J. (2020). Public perceptions of COVID-19 in Australia: Perceived risk, knowledge, health-protective behaviors, and vaccine intentions. *Frontiers in Psychology*. <https://doi.org/10.3389/fpsyg.2020.551004>.
- Finnish Government. (2020a). Government, in cooperation with the President of the Republic, declares a state of emergency in Finland over coronavirus outbreak. Retrieved from <https://valtioneuvosto.fi/en/-/10616/uudellemaalle-liikumisrajoituksia-hallitus-paatti-uusista-lisatoimista-koronaepidemiaan-leviamisen-estamiseksi>.
- Finnish Government. (2020b). Movement restrictions to Uusimaa - the Government decided on further measures to prevent the spread of the coronavirus epidemic. Retrieved from <https://valtioneuvosto.fi/en/-/10616/uudellemaalle-liikumisrajoituksia-hallitus-paatti-uusista-lisatoimista-koronaepidemiaan-leviamisen-estamiseksi>.
- Finnish Institute for Health and Welfare. (2020). Confirmed coronavirus cases (COVID-19) in Finland. Retrieved from <https://experience.arcgis.com/experience/92e9bb33fac744c9a084381fc35aa3c7>.
- Freeman, D., Loe, B. S., Chadwick, A., Vaccari, C., Waite, F., Rosebrock, L., ... Lambe, S. (2020). COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychological Medicine*. <https://doi.org/10.1017/S0033291720005188>.
- Galasso, V., Pons, V., Profeta, P., Becher, M., Brouard, S., & Foucault, M. (2020). Gender differences in COVID-19 attitudes and behavior: Panel evidence from eight countries. *PNAS*, 117(44), 27285–27291. <https://doi.org/10.1073/pnas.2012520117>.
- Glöckner, A., Dorrough, A., Wingen, T., & Dohle, S. (2020). The perception of infection risks during the early and later outbreak of COVID-19 in Germany: Consequences and recommendations. In *PsyArXiv*. Retrieved from <https://psyarxiv.com/wdbgc/>.
- Griffith, D. M., Sharma, G., Holliday, C. S., Enyia, O. K., Valliere, M., Semlow, A. R., ... Blumenthal, R. S. (2020). Men and COVID-19: A biopsychosocial approach to understanding sex differences in mortality and recommendations for practice and

- policy interventions. *Preventing Chronic Disease*, 17. <https://doi.org/10.5888/pcd17.200247>.
- Harapan, H., Mudatsir, M., Yufika, A., Nawawi, Y., Wahyuniati, N., Anwar, S., ... Imrie, A. (2019). Community acceptance and willingness-to-pay for a hypothetical Zika vaccine: A cross-sectional study in Indonesia. *Vaccine*, 37(11), 1398–1406. <https://doi.org/10.1016/j.vaccine.2019.01.062>.
- Harper, C. A., Satchell, L. P., Fido, D., & Latzman, R. D. (2020). Functional fear predicts public health compliance in the COVID-19 P pandemic. *International Journal of Mental Health and Addiction*. <https://doi.org/10.1007/s11469-020-00281-5>.
- Karafilakis, E., & Larson, H. J. (2017). The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. *Vaccine*, 35(37), 4840–4850. <https://doi.org/10.1016/j.vaccine.2017.07.061>.
- Karlsson, L., Tolvanen, M., Scheinin, N. M., Uusitupa, H.-M., Korja, R., Ekholm, E., ... Karlsson, H., & FinnBrain Birth Cohort Study Group. (2018). Cohort profile: The FinnBrain birth cohort study (FinnBrain). *International Journal of Epidemiology*, 47(1), 15–16j. <https://doi.org/10.1093/ije/dyx173>.
- Karlsson, L. C., Lewandowsky, S., Antfolk, J., Salo, P., Lindfelt, M., Oksanen, T., ... Soveri, A. (2019). The association between vaccination confidence, vaccination behavior, and willingness to recommend vaccines among Finnish healthcare workers. *PLoS ONE*, 14(10), 1–17. <https://doi.org/10.1371/journal.pone.0224330>.
- Kwok, K. O., Li, K. K., Chan, H. H. H., Yi, Y. Y., Tang, A., Wei, W. I., & Wong, S. Y. S. (2020). Community responses during early phase of COVID-19 epidemic, Hong Kong. *Emerging Infectious Diseases*, 26(7), 1575–1579. <https://doi.org/10.3201/eid2607.200500>.
- Larson, H. J., Jarrett, C., Eckersberger, E., Smith, D. M. D., & Paterson, P. (2014). Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. *Vaccine*, 32(19), 2150–2159. <https://doi.org/10.1016/j.vaccine.2014.01.081>.
- Loewenstein, G. F., Weber, E. U., Hsee, C. K., & Welch, N. (2001). Risk as feelings. *Psychological Bulletin*, 127(2), 267–286. <https://doi.org/10.1037/0033-2909.127.2.267>.
- MacDonald, N. E., & the SAGE Working Group on Vaccine Hesitancy. (2015). Vaccine hesitancy: Definition, scope and determinants. *Vaccine*, 33(34), 4161–4164. <https://doi.org/10.1016/j.vaccine.2015.04.036>.
- Malik, A. A., McFadden, S. M., Elharake, J., & Omer, S. B. (2020). Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine*, 26. <https://doi.org/10.1016/j.eclinm.2020.100495>.
- Murphy, J., Vallières, F., Bentall, R. P., Shevlin, M., McBride, O., Hartman, T., ... Hyland, P. (2020). Preparing for a COVID-19 vaccine: Identifying and psychologically profiling those who are vaccine hesitant or resistant in two general population samples. In *PsyArXiv*. Retrieved from <https://psyarxiv.com/pev2b/>.
- Neumann-Böhme, S., Varghese, N. E., Sabat, I., Barros, P. P., Brouwer, W., van Exel, J., ... Stargardt, T. (2020). Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. *The European Journal of Health Economics*, 21, 977–982. <https://doi.org/10.1007/s10198-020-01208-6>.
- Ophir, Y., & Jamieson, K. H. (2018). Intentions to use a novel Zika vaccine: The effects of misbeliefs about the MMR vaccine and perceptions about Zika. *Journal of Public Health*, 40(4), e531–e537. <https://doi.org/10.1093/pubmed/fty042>.
- Park, T., Ju, I., Ohs, J. E., & Hinsley, A. (2020). Optimistic bias and preventive behavioral engagement in the context of COVID-19. *Research in Social and Administrative Pharmacy*. <https://doi.org/10.1016/j.sapharm.2020.06.004>.
- R Core Team. (2018). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing. Retrieved from <https://www.r-project.org/>.
- Sarkonen, T., Alakuijala, A., Julkunen, I., & Partinen, M. (2018). Narcolepsy associated with Pandemrix vaccine. *Current Neurology and Neuroscience Reports*, 18(43). <https://doi.org/10.1007/s11910-018-0851-5>.
- Schmid, P., Rauber, D., Betsch, C., Lidolt, G., & Denker, M.-L. (2017). Barriers of influenza vaccination intention and behavior-A systematic review of influenza vaccine hesitancy, 2005–2016. *PLoS ONE*, 12(1), 1–46. <https://doi.org/10.1371/journal.pone.0170550>.
- Slovic, P., Finucane, M. L., Peters, E., & MacGregor, D. G. (2004). Risk as analysis and risk as feeling: Some thoughts about affect, reason, risk and rationality. *Risk Analysis*, 24(2), 311–322. <https://doi.org/10.1111/j.0272-4332.2004.00433.x>.
- The COCONEL Group. (2020). A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. *The Lancet Infectious Diseases*, 20(7), 769–770. [https://doi.org/10.1016/S1473-3099\(20\)30426-6](https://doi.org/10.1016/S1473-3099(20)30426-6).
- Thomson, A., Robinson, K., & Vallée-Tourangeau, G. (2016). The 5As: A practical taxonomy for the determinants of vaccine uptake. *Vaccine*, 34(8), 1018–1024. <https://doi.org/10.1016/j.vaccine.2015.11.065>.
- Wang, Y., McKee, M., Torbica, A., & Stuckler, D. (2019). Systematic literature review on the spread of health-related misinformation on social media. *Social Science and Medicine*, 240. <https://doi.org/10.1016/j.socscimed.2019.112552>.
- Ward, J. K., Alleaume, C., Peretti-watel, P., & the COCONEL Group. (2020). The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue. *Social Science & Medicine*, 265. <https://doi.org/10.1016/j.socscimed.2020.113414>.
- Weinstein, N. D., Kwitel, A., Mccaull, K. D., Magnan, R. E., Gerrard, M., & Gibbons, F. X. (2007). Risk perceptions: Assessment and relationship to influenza vaccination. *Health Psychology*, 26(2), 146–151. <https://doi.org/10.1037/0278-6133.26.2.146>.
- WHO. (2020a). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Retrieved from <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020>.
- WHO. (2020b). WHO Director-General's opening remarks at the media briefing on COVID-19 - 3 March 2020. Retrieved from [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-3-march-2020?fbclid=IwAR2F5vbw2\\_Jd6GfaxlqJx4OttOy\\_QfSUayAfMLimhgBfPzRq5cLVnGC5x2k](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-3-march-2020?fbclid=IwAR2F5vbw2_Jd6GfaxlqJx4OttOy_QfSUayAfMLimhgBfPzRq5cLVnGC5x2k).
- Wise, T., Zbozinek, T. D., Michelini, G., Hagan, C. C., & Mobbs, D. (2020). Changes in risk perception and self-reported protective behaviour during the first week of the COVID-19 pandemic in the United States. *Royal Society Open Science*, 7. <https://doi.org/10.1098/rsos.200742>.